The use of the Sputnik Light vaccine halves the risk of contracting coronavirus infection, said the director of the Center.

Gamalei Alexander Gunzburg.

"If the Light option, which is the first component of the Sputnik V vaccine, is used separately without a second vaccination, then this makes it possible to reduce the disease with this infection by 50 percent, or even 60 percent," RIA Novosti quotes him.

Recall that the Ministry of Health of the Russian Federation began to register the SARS-CoV-2 vaccine under the name "Sputnik Light" on March 29.

As explained earlier in the Russian Direct Investment Fund (RDIF), "Sputnik Light", is a one-component version of the drug registered in Russia from COVID-19 "Sputnik V".

Also on russian.rt.com "Against all variants of the virus known so far": Putin announced the effectiveness of the Russian vaccine "Sputnik V"

As noted in the Center.

Gamalea, stable immunity from the use of "Sputnik Light" is formed within three weeks and lasts for three to four months.

Meanwhile, interest in vaccination is growing in Russia, said Deputy Prime Minister Tatyana Golikova.

It is especially important to vaccinate before spring and summer, she said.

“The number of citizens wishing to be vaccinated has increased dramatically ... Therefore, it is necessary to vaccinate in order to take care of yourself and your loved ones, especially on the eve of the spring-summer season,” said the program “Moscow.

Kremlin.

Putin "on the TV channel" Russia 1 ".

Meanwhile, foreign interest in the main version of the Sputnik V vaccine is also growing.

In early April, it became known that the drug was already registered in 59 countries with a total population of over 1.5 billion people.

The RDIF said that by now there are agreements on the release of the vaccine with ten countries and with 20 manufacturers, including the largest in the world.

During a meeting with Vladimir Putin, the head of the Russian Direct Investment Fund Kirill Dmitriev said that in April many of the companies producing Russian drugs abroad will reach full capacity.

As the executive director of the WHO European Office Robb Butler said earlier in an interview with RT, the Russian vaccine has become a real salvation for a number of countries.  

"It (Sputnik V. -

RT

) is used by many Member States (WHO. -

RT

), and for those countries that do not have access to drugs, the Russian vaccine has become a real salvation," Butler emphasized.

The situation around the AstraZeneca vaccine

Meanwhile, it became known that the Emergent Biosolutions plant in the American Baltimore will stop producing the British-Swedish vaccine AstraZeneca, focusing on the production of the drug from the American company Johnson & Johnson.

According to The New York Times, the administration of US President Joe Biden has decided to transfer control of the plant to Johnson & Johnson.

This information is confirmed by a press release from the corporation, which states that Johnson & Johnson "takes full responsibility" for the production of vaccines at the Emergent Biosolutions facility.

According to the newspaper, until recently, the plant produced AstraZeneca and Johnson & Johnson vaccines in parallel.

However, 15 million doses of Johnson & Johnson's vaccine were spoiled due to the mistaken mixing of two vaccines produced at the plant.

AstraZeneca issued a statement confirming the information about the termination of the release of the drug at the plant in Baltimore.

Recall that at the end of March, the AstraZeneca vaccine officially changed its name.

The drug is now called Vaxzevria.

This decision became known against the backdrop of many refusals of European countries to use the drug due to the identification of side effects.

In particular, in a number of countries, cases of blood clots and blood clotting disorders were recorded in patients who were vaccinated with the drug.

In some cases, these circumstances have led to deaths.

So, in March about the suspension of the use of the AstraZeneca vaccine in a number of European countries.

According to the company's position, there was no evidence of a link between drug use and an increased risk of blood clots.

The company said that of the approximately 17 million vaccinated citizens in the EU and the UK, the number of patients who develop blood clots is "lower than the hundreds of cases that would be expected in the general population."

Subsequently, the European Medicines Agency (EMA) conducted its own review.

The agency said a possible link between coronavirus vaccination with the drug, AstraZeneca, and blood clots has not been proven at this time, but it is possible.

Further analysis is needed, the EMA noted.